Page 113 - Read Online

Page 16 of 19 Davidson et al. J Cancer Metastasis Treat 2021;7:45 https://dx.doi.org/10.20517/2394-4722.2021.77

42. Chen X, Chen S, Yu D. Protein kinase function of pyruvate kinase M2 and cancer. Cancer Cell Int 2020;20:523. DOI PubMed
PMC
43. Zhang Z, Deng X, Liu Y, Liu Y, Sun L, Chen F. PKM2, function and expression and regulation. Cell Biosci 2019:9. DOI PubMed
PMC
44. Yang J, Liu H, Liu X, Gu C, Luo R, Chen HF. Synergistic allosteric mechanism of fructose-1,6-bisphosphate and serine for pyruvate
kinase M2 via dynamics fluctuation network analysis. J Chem Inf Model 2016;56:1184-92. DOI PubMed PMC
45. Chaneton B, Hillmann P, Zheng L, et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature
2012;491:458-62. DOI PubMed PMC
46. Keller KE, Doctor ZM, Dwyer ZW, Lee YS. SAICAR induces protein kinase activity of PKM2 that is necessary for sustained
proliferative signaling of cancer cells. Mol Cell 2014;53:700-9. DOI PubMed PMC
47. Yang Q, Ji M, Guan H, Shi B, Hou P. Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling
pathways. J Clin Endocrinol Metab 2013;98:E1909-17. DOI PubMed
48. Zhao X, Zhu Y, Hu J, et al. Shikonin inhibits tumor growth in mice by suppressing pyruvate kinase M2-mediated aerobic glycolysis.
Sci Rep 2018;8:14517. DOI PubMed PMC
49. Feng C, Gao Y, Wang C, et al. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the
BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 2013;98:E1524-33. DOI PubMed
50. Gao Y, Yang F, Yang XA, et al. Mitochondrial metabolism is inhibited by the HIF1α-MYC-PGC-1β axis in BRAF V600E thyroid
cancer. FEBS J 2019;286:1420-36. DOI PubMed
51. Mirebeau-Prunier D, Le Pennec S, Jacques C, et al. Estrogen-related receptor alpha modulates lactate dehydrogenase activity in
thyroid tumors. PLoS One 2013;8:e58683. DOI PubMed PMC
52. Kachel P, Trojanowicz B, Sekulla C, Prenzel H, Dralle H, Hoang-Vu C. Phosphorylation of pyruvate kinase M2 and lactate
dehydrogenase A by fibroblast growth factor receptor 1 in benign and malignant thyroid tissue. BMC Cancer 2015;15:140. DOI
PubMed PMC
53. Coelho RG, Cazarin JM, Cavalcanti de Albuquerque JP, de Andrade BM, Carvalho DP. Differential glycolytic profile and Warburg
effect in papillary thyroid carcinoma cell lines. Oncol Rep 2016;36:3673-81. DOI PubMed
54. Gill KS, Tassone P, Hamilton J, et al. Thyroid cancer metabolism: a review. J Thyroid Disord Ther 2016;5:200. DOI PubMed PMC
55. Johnson JM, Lai SY, Cotzia P, et al. Mitochondrial metabolism as a treatment target in anaplastic thyroid cancer. Semin Oncol
2015;42:915-22. DOI PubMed PMC
56. Fu Y, Liu S, Yin S, et al. The reverse Warburg effect is likely to be an Achilles' heel of cancer that can be exploited for cancer
therapy. Oncotarget 2017;8:57813-25. DOI PubMed PMC
57. Rousset M, Zweibaum A, Fogh J. Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of
various tissue origins. Cancer Res 1981;41:1165-70. PubMed
58. Zois CE, Harris AL. Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer
therapy. J Mol Med (Berl) 2016;94:137-54. DOI PubMed PMC
59. Shulman RG, Rothman DL. The glycogen shunt maintains glycolytic homeostasis and the warburg effect in cancer. Trends Cancer
2017;3:761-7. DOI PubMed
60. Dauer P, Lengyel E. New roles for glycogen in tumor progression. Trends Cancer 2019;5:396-9. DOI PubMed
61. Ahn CS. Glycogen metabolism of the thyroid. Endocrinology 1971;88:1341-8. DOI PubMed
62. Carcangiu ML, Sibley RK, Rosai J. Clear cell change in primary thyroid tumors. A study of 38 cases. Am J Surg Pathol 1985;9:705-
22. DOI PubMed
63. Pelletier J, Bellot G, Gounon P, Lacas-Gervais S, Pouysségur J, Mazure NM. Glycogen synthesis is induced in hypoxia by the
hypoxia-inducible factor and promotes cancer cell survival. Front Oncol 2012;2:18. DOI PubMed PMC
64. Adeva-Andany MM, González-Lucán M, Donapetry-García C, Fernández-Fernández C, Ameneiros-Rodríguez E. Glycogen
metabolism in humans. BBA Clin 2016;5:85-100. DOI PubMed PMC
65. Andersen B, Rassov A, Westergaard N, Lundgren K. Inhibition of glycogenolysis in primary rat hepatocytes by 1, 4-dideoxy-1,4-
imino-D-arabinitol. Biochem J 1999;342 Pt 3:545-50. PubMed PMC
66. Jakobsen P, Lundbeck JM, Kristiansen M, et al. Iminosugars: potential inhibitors of liver glycogen phosphorylase. Bioorganic &
Medicinal Chemistry 2001;9:733-44. DOI PubMed
67. Martin WH, Hoover DJ, Armento SJ, et al. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in
vivo. Proc Natl Acad Sci U S A 1998;95:1776-81. DOI PubMed PMC
68. Schnier JB, Nishi K, Monks A, Gorin FA, Bradbury E. Inhibition of glycogen phosphorylase (GP) by CP-91,149 induces growth
inhibition correlating with brain GP expression. Biochemical and Biophysical Research Communications 2003;309:126-34. DOI
PubMed
69. Barot S, Abo-Ali EM, Zhou DL, Palaguachi C, Dukhande VV. Inhibition of glycogen catabolism induces intrinsic apoptosis and
augments multikinase inhibitors in hepatocellular carcinoma cells. Exp Cell Res 2019;381:288-300. DOI PubMed
70. Schnier JB, Nishi K, Gumerlock PH, Gorin FA, Bradbury EM. Glycogen synthesis correlates with androgen-dependent growth arrest
in prostate cancer. BMC Urol 2005;5:6. DOI PubMed PMC
71. Sanchez-Sanchez AM, Antolin I, Puente-Moncada N, et al. Melatonin cytotoxicity is associated to warburg effect inhibition in ewing
sarcoma cells. PLoS One 2015;10:e0135420. DOI PubMed PMC
72. Lee WN, Guo P, Lim S, et al. Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor
treatment. Br J Cancer 2004;91:2094-100. DOI PubMed PMC